New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 28, 2013
16:30 EDTAMRNAmarin believes Vascepa well positioned in triglyceride lowering market
Amarin believes that Vascepa is well positioned to compete in the triglyceride lowering market. This is a large market which, based on market research, Amarin believes is currently underpenetrated due to limitations of existing therapies. Amarin's market research further suggests that clinicians value the data supporting Vascepa in the MARINE indication: in patients with very high (=500 mg/dL) triglyceride levels, Vascepa has been shown to lower triglycerides without increasing bad cholesterol (low-density lipoprotein cholesterol, or LDL-C) and with a tolerability and safety profile similar to placebo. Amarin formally launched Vascepa in the United States on January 28.
News For AMRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 20, 2015
05:51 EDTAMRNStocks with implied volatility movement; AMRN EWG
Stocks with implied volatility movement; Amarin (AMRN) 140, iShares MSCI Germany (EWG) 20 according to iVolatility.
March 17, 2015
08:54 EDTAMRNAmarin says study suggest EPA pretreatment reduces oxidative damage
Subscribe for More Information
March 16, 2015
10:07 EDTAMRNHigh option volume stocks
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use